NCT06047574 Multidisciplinary Diagnosis and Treatment of Polycystic Ovary Syndrome
| NCT ID | NCT06047574 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai 10th People's Hospital |
| Condition | Polycystic Ovary Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2023-09-18 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2023-09-18 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators collected clinical data and serum samples of patients with polycystic ovary syndrome (PCOS) in this study, used statistical software such as SPSS for date analysis, and used experimental techniques such as ELISA and flow cytometry to detect serum samples, aiming to explore the relationship between the body anthropometry, skin conditions, psychosomatic status, diet, sleep, exercise, glucose and lipid metabolism, gonadal hormones, and body fat distribution in patients with polycystic ovary syndrome, and to discovery new biomarkers. Multidisciplinary exploration of the mechanisms of disease occurrence and development, the establishment of a PCOS multicenter, multidisciplinary and multidimensional clinical research database, combined with the established statistical analysis strategy for big data and analysis, to promote the realization of more accurate personalized medicine.
Eligibility Criteria
Inclusion Criteria: * Female aged 18- 45; Exclusion Criteria: * Female patients younger than 18 years old or older than 45 years old; * Ovulatory disorders caused by premature ovarian failure, pituitary amenorrhea, hypothalamic amenorrhea, and thyroid dysfunction; * Congenital adrenal hyperplasia, reservoir Hin syndrome, hyperprolactinemia, adrenal tumors and other diseases that cause hyperandrogenism; * Abnormal liver or renal function((≥ 3 times of the upper limit of normal range) * Type 1 diabetes, single gene mutation diabetes, or pancreatic damage Diabetes or other secondary diabetes caused by diabetes; * History of malignant tumors; * Severe infection, severe anemia, neutropenia and other systemic chronic diseases; * Undergo total hysterectomy or ovarian adnexectomy; * Mental illness, dementia or other cognitive behavioral problems; * Use hypoglycemic drugs that may affect insulin resistance and androgen levels in the last 3 months, including thiazolidinediones, metformin, SGLT-2, and acarbose and GLP-1RA and other drugs; * Use letrozole, clomiphene, oral contraceptives, glucocorticoids, gonadotropins, gonadotropin-releasing hormone agonists, anti-androgens (spironolactone, Cyproterone acetate, flutamide, etc.) and other drugs for the treatment of PCOS.
Contact & Investigator
Shen Qu, Dr
STUDY CHAIR
Shanghai 10th People's Hospital
Frequently Asked Questions
Who can join the NCT06047574 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Polycystic Ovary Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06047574 currently recruiting?
Yes, NCT06047574 is actively recruiting participants. Contact the research team at mannazhang@126.com for enrollment information.
Where is the NCT06047574 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06047574 clinical trial?
NCT06047574 is sponsored by Shanghai 10th People's Hospital. The principal investigator is Shen Qu, Dr at Shanghai 10th People's Hospital. The trial plans to enroll 3,000 participants.